Register today for a LIVE national broadcast on New Treatment Options for Rare Diseases in the Soft Tissue for March 5th and 6th!

Hispanics Are at Highest Risk of Neurotoxicity From Chemotherapy for ALL

Audrey Sternberg
Published: Monday, Nov 12, 2018
Michael E. Scheurer, PhD, MPH

Michael E. Scheurer, PhD, MPH

Ethnic differences in the prevalence of neurotoxicity from methotrexate therapy may help explain why minority patients, specifically Hispanics, experience disparities in treatment outcomes for pediatric acute lymphoblastic leukemia (ALL), according to study results published in Clinical Cancer Research.1

Limitations to the study include its short timeline, said Scheurer, since there are insufficient data to evaluate the long-term effects of neurotoxicity. A larger study with more non-Hispanic black and Asian patients would help investigators better understand the issue, he added.

References

  1. Taylor OA, Brown AL, Brackett J, et al. Disparities in neurotoxicity risk and outcomes among pediatric acute lymphoblastic leukemia patients. Clin Cancer Res. 2018;24(20):5012-5017. doi: 10.1158/1078-0432.CCR-18-0939.
  2. Hispanic children more likely to experience neurotoxicity during treatment for acute lymphoblastic leukemia [news release]. Philadelphia, PA: American Association for Cancer Research; September 11, 2018. aacr.org/Newsroom/Pages/News-Release-Detail.aspx?ItemID=1218. Accessed October 4, 2018.

... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication
x